#United States #Anixa Biosciences #San Jose #CAR-T therapy #Cancer Vaccines

Anixa Biosciences to Showcase Innovations at CEO Forum

Anixa Biosciences, Inc., renowned for its commitment to cancer treatment and prevention, is scheduled to participate in the prestigious 18th Annual European Life Sciences CEO Forum, which will be held on February 26-27, 2025, at the Hilton Zurich Airport Hotel in Zurich, Switzerland. This annual event gathers leading executives, investors, and industry experts from the life sciences arena to explore the latest advancements and trends influencing the industry.

Mike Catelani, Anixa's President and CFO, will represent the company at this conference, where he is set to discuss recent developments in Anixa’s pipeline. This includes a focus on groundbreaking CAR-T therapy for ovarian cancer in collaboration with Moffitt Cancer Center, as well as a breast cancer vaccine that has been developed in partnership with Cleveland Clinic. The presentation aims to highlight Anixa's expanding portfolio, which includes several cancer vaccine programs targeting various difficult-to-treat malignancies.

Key Details of the Presentation

• - Event: 18th Annual European Life Sciences CEO Forum
• - Location: Hilton Zurich Airport Hotel
• - Date: February 27, 2025
• - Time: 10:40 AM CET

During the presentation, Catelani will shed light on Anixa's recent clinical advancements and strategic initiatives, which are designed to accelerate the development of their innovative therapies. He also looks forward to engaging with potential partners and investors in one-on-one meetings throughout the event.

The CEO expressed his enthusiasm: "We are excited to participate in this prestigious event and share updates on our cutting-edge programs. As we continue to advance our pipeline, we look forward to collaborating with investors and industry leaders who share our dedication to developing innovative and life-changing oncology therapies."

About Anixa Biosciences, Inc.

Anixa is a clinical-stage biotechnology firm dedicated to developing treatments and preventive measures for cancer. The company takes pride in its therapeutic portfolio, including an ovarian cancer immunotherapy program developed with Moffitt Cancer Center, utilizing a unique CAR-T technology termed chimeric endocrine receptor-T cell (CER-T). Anixa’s vaccine initiatives involve collaborations with Cleveland Clinic targeted at preventing breast and ovarian cancers, along with additional vaccines aimed at several difficult-to-treat cancers, including lung, colon, and prostate cancers. The company's unique approach involves forming partnerships with esteemed research institutions at every stage of development.

To stay updated, visit Anixa's official website and follow their social media channels on Twitter, LinkedIn, Facebook, and YouTube for real-time news and insights.

Forward-Looking Statements

It is important to note that certain statements made during the forum may be characterized as forward-looking. These statements reflect Anixa’s current expectations regarding future events and results and are subject to various risks and uncertainties. Factors that could cause actual results to differ significantly include those outlined in the company's recent filings with the SEC. The company does not undertake any obligation to update forward-looking statements, except as required by law.

For more information, interested parties can contact Mike Catelani, President, COO, and CFO, at [email@example.com] or via phone at 408-708-9808.